SDK to Enter Purification Resin Market through Strategic Investment
Complete the form below to unlock access to ALL audio articles.
Showa Denko K.K. (SDK) has signed a strategic partnership agreement with BIA Separations (BIASep), of Austria.
The partnership includes SDK’s investment in BIASep as well as joint marketing and R&D.
With the partnership, SDK will be ready to expand its business to a market of purification resins used for manufacturing biopharmaceuticals and for industrial applications.
SDK is conducting a separation/refining business, developing, manufacturing, and selling various products pertaining to high-performance liquid chromatography (HPLC).
SDK has been providing a wide variety of analytical HPLC columns with the brand name of “Shodex™” for more than 40 years.
The Shodex™ columns are delivered to wide-ranging customers in the world, including public institutions and R&D/quality control sectors of private enterprises, through the Showa Denko Group’s global sales network.
This time, SDK decided to enter the purification resin market through the strategic partnership with BIASep, expecting to achieve good synergistic effect in terms of both technology and product mix.
The market is expected to grow rapidly with the expansion of the biopharmaceutical industry. SDK will fully utilize the technologies it has amassed through the Shodex™ business to enhance the synergies.
Purification resins are used for refining desired components/chemicals from culture/reaction solutions for biopharmaceutical and industrial manufacturing processes.
SDK’s protein analysis technology and know-how acquired through the Shodex™ business will be fully utilized, as protein purification plays a key role in the purifying process for biopharmaceuticals.
Efficiency in purification is generally low, resulting in high production costs of biopharmaceuticals. However, BIASep has developed CIM® Monoliths (CIM Convective Interaction Media®), which ensure more efficient purification, compared with competitors’ purification resins.
SDK has judged that it is best to enter into a tie-up with BIASep to realize a participation in the purification resin market.
Through the partnership arrangement with BIASep, SDK will acquire know-how concerning development, production, quality control, and marketing of purification resins.
Furthermore, SDK will aim to strengthen business relations with producers of biopharmaceuticals, thereby expanding its separation/refining business.
